Key result
Morbidly obese patients with NASH show ~28% lower liver adiponectin expression vs simple steatosis.
Why the study?
The role of adiponectin and its receptors in the development and progression of NAFLD in morbidly obese patients was unknown.
Population
30 morbidly obese patients with NAFLD (18 NASH vs 12 steatosis)
Comparison
NASH vs simple steatosis
Design
Cross-sectional analysis of liver biopsies
Authors
Loading...
Should not change NAFLD management; supports hypothesis-generating studies on adiponectin in NASH progression.
Cross-Sectional (n=30)
Absolute Event Rate: 1.61% vs 2.25%
p-value: p=0.028
Decreased liver adiponectin expression is associated with the severity of NAFLD, specifically the progression from simple steatosis to NASH in morbidly obese patients.
Ma et al. (2008) conducted a cross-sectional in Non-alcoholic fatty liver disease (NAFLD) (n=30). NASH vs. Simple steatosis was evaluated on Liver adiponectin expression (p=0.028). Liver adiponectin expression was significantly lower in morbidly obese patients with NASH compared to those with simple steatosis (1.61 vs 2.25, P=0.028).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: